India, Pakistan and Cambodia Human Immunodeficiency Virus (HIV) Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

India, Pakistan & Cambodia Human Immunodeficiency Virus (HIV) Treatment Market is segmented By Drug Type (NRTs, NNRTs, Protease Inhibitors, Entry Inhibitors, HIV Integrase Strand Transfer Inhibitors, Multi-Class Combination Drugs, Others), By End-User (Hospitals, Speciality Clinics, NGOs, Others)  – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

The India, Pakistan, and Cambodia human immunodeficiency virus treatment market reached US$ 4.8 billion in 2023 and is expected to reach US$ 6.7 billion by 2031, growing at a CAGR of 4.5% during the forecast period 2024-2031.

HIV (human immunodeficiency virus) is a virus that attacks cells that help the body fight infection, making a person more vulnerable to other infections and diseases. It is spread by contact with certain bodily fluids of a person with HIV, most commonly sexually transmitted, or through sharing injection drug equipment. The human body can’t get rid of HIV and no effective HIV cure exists. 

AIDS is a disease caused by the damage that HIV does to the immune system. A person with HIV is considered to have progressed to AIDS when the number of their CD4 cells falls below 200 cells per cubic millimeter of blood (200 cells/mm3) or they develop one or more opportunistic infections regardless of their CD4 count. In a person with a healthy immune system, CD4 counts are between 500 and 1,600 cells/mm3. If the infection is not treated, it becomes a chronic HIV infection. Often, there are no symptoms during this stage. If it is not treated, eventually the virus will weaken your body's immune system. Then the infection will progress to AIDS. This is the late stage of HIV infection.

Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers

Increasing prevalence of HIV infections

The demand for the India, Pakistan, and Cambodia human immunodeficiency virus treatment market is driven by multiple factors. The rising prevalence of HIV infections propels the market growth. 

Furthermore, the demand for treatment will be fueled by technological advancements, as well as increasing government initiatives and funding. For instance, according to the estimates posted by unaids.org in 2023,  there are 25,00,000 adults and children living with HIV in India. There are 68,000 adults and children newly infected in the previously mentioned statistics. There are 36,000 deaths due to AIDS in 2023. The prevalence rate is 0.3. For instance, according to the estimates posted by unaids.org in 2023,  there are 2,90,000 adults and children living with HIV in Pakistan. There are 11,000 deaths in Pakistan due to AIDS. 

And the anti-retroviral therapy coverage in Pakistan is 99.2%. The HIV prevalence percentage in Pakistan is 2%. The anti-retroviral therapy coverage in India is 70%. For instance, according to the estimates posted by unaids.org in 2023, there are 76,000 adults and children living with HIV in Cambodia. The anti-retroviral therapy coverage in Cambodia is 100%. There are 1,200 adults and children newly infected in the previously mentioned statistics. 

Restraints

Factors such as lack of awareness among people, and stringent regulatory requirements for the approval of new treatments are expected to hamper the market. 

Market Segment Analysis

The India, Pakistan, and Cambodia human immunodeficiency virus treatment market is segmented based on drug type and end-user.

The segment nucleoside reverse transcriptase inhibitors (NRTs) accounted for approximately 53.2% of the India, Pakistan, and Cambodia human immunodeficiency virus treatment market share

The nucleoside reverse transcriptase inhibitors (NRT's) segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and rising funds for private manufacturers for research works and clinical trials would drive this market. 

Nucleoside reverse transcriptase inhibitors (NRTIs) block reverse transcriptase (an HIV enzyme). HIV uses reverse transcriptase to convert its RNA into DNA (reverse transcription). Blocking reverse transcriptase and reverse transcription prevents HIV from replicating. Reverse transcriptase inhibitors are medications used in the management and treatment of HIV. It is in the antiretroviral class of drugs.

For instance, according to an article posted by nih.gov in June 2023, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) were the first class of antiretroviral drugs to be approved by the FDA. NRTIs are taken as prodrugs and must be taken into the host cell and phosphorylated before they become active. To date, the FDA has approved the use of reverse transcriptase inhibitors for two main viral infections. The first approved use is for the treatment of HIV, specifically the HIV-1 strain. 

Market Segmentation

By Drug Type

• Nucleoside Reverse Transcriptase Inhibitors (NRT's)
• Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's)
• Protease Inhibitors
• Entry Inhibitors
• HIV Integrase Strand Transfer Inhibitors
• Multi-class Combination Drugs
• Others 

By End-User

• Hospitals
• Speciality Clinics
• Others

Market Competitive Landscape

The major players in the India, Pakistan, and Cambodia human immunodeficiency virus treatment market include Merck & Co., Bristol-Myers Squibb Company, Johnson & Johnson, F. Hoffmann-La F. Hoffmann-La Roche Ltd. Ltd, Boehringer Ingelheim, GlaxoSmithKline plc, and Mylan Pharmaceutical, Aetos Pharma Private Limited, Cipla, and Aurobindo Pharma among others.

Key Developments

• In July 2024, global pharma major Lupin announced that it received tentative approval from the United States Food and Drug Administration (U.S. FDA) under the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application for Emtricitabine and Tenofovir Alafenamide Tablets, 200 mg/25 mg. This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries. Emtricitabine and Tenofovir Alafenamide Tablets are indicated to treat or prevent HIV-1 infection in adults and children who weigh at least 35 kg.
• In April 2024, ten years after the signing of ground-breaking licensing agreements between ViiV Healthcare and the Medicines Patent Pool (MPP), as well as the direct agreements with Aurobindo Pharma and ViiV Healthcare, more than 1 billion packs of generic dolutegravir (DTG)- based medicines have reached 24 million people living with HIV in 128 low- and middle-income countries (LMICs), transforming the HIV landscape in those areas of the world. This means that as of 2023, over 90% of people on antiretroviral treatment in these countries are estimated to be on DTG-based regimens.

Why Purchase the Report?

• To visualize the India, Pakistan, and Cambodia human immunodeficiency virus treatment market segmentation based on drug type and end-user as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of India, Pakistan, and Cambodia human immunodeficiency virus (HIV) treatment market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The India, Pakistan, and Cambodia human immunodeficiency virus treatment market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies